Meeting
2024 ASCO Genitourinary Cancers Symposium
Effect of combined treatment with sipuleucel-T and IL-15 on tumor control, tumor-infiltrating immune effectors, and key mediators of immunoresistance in a preclinical prostate cancer model.
Authors
Russell Kent Pachynski
Washington University School of Medicine, St. Louis, MO
Russell Kent Pachynski , Muhammad Azeem Saeed , Bo Peng , Brian Andrew Van Tine , Nadeem Anwar Sheikh , Todd A. Fehniger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 177)
DOI
10.1200/JCO.2024.42.4_suppl.177
Abstract #
177
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of camelid B7-H3 tri-specific killer engagers on natural killer cells in patients with prostate cancer.
First Author: Nicholas Zorko
Poster
2023 ASCO Annual Meeting
HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.
First Author: David D. Chism
Poster
2021 ASCO Annual Meeting
Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells.
First Author: Joshua W. Keegan
Poster
2014 Genitourinary Cancers Symposium
Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer.
First Author: Charles G. Drake